Stockscreener 앱 받기
135.87
1.29%
-1.77
시장 영업 전:
135.71
-0.16
-0.12%
전일 마감가:
$137.64
열려 있는:
$138.055
하루 거래량:
3.86M
Relative Volume:
0.56
시가총액:
$168.64B
수익:
$29.45B
순이익/손실:
$8.51B
주가수익비율:
20.03
EPS:
6.7823
순현금흐름:
$9.46B
1주 성능:
-2.27%
1개월 성능:
-0.98%
6개월 성능:
+10.36%
1년 성능:
+29.97%
1일 변동 폭
$135.48
$138.54
1주일 범위
$135.48
$141.40
52주 변동 폭
$93.37
$157.29
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
135.87 | 170.84B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
919.90 | 828.17B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
230.69 | 564.05B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
203.71 | 368.57B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
200.69 | 317.61B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
117.10 | 294.09B | 64.93B | 18.26B | 12.36B | 7.2751 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-11 | 재확인 | Needham | Buy |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors - Yahoo Finance UK
Lobbying Update: $3,190,000 of GILEAD SCIENCES INC lobbying was just disclosed - Quiver Quantitative
Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch
Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 EarningsBut Won't (NASDAQ:GILD) - Seeking Alpha
Leerink cuts Arcus Biosciences stock price target on Gilead collaboration end - Investing.com Canada
Gilead Sciences stock edges lower as company discusses expanding oncology reach at AACR26 - Traders Union
Arcus halts Gilead-partnered late-stage trial (RCUS:NYSE) - Seeking Alpha
Arcus Ends Key Lung Cancer Trials in Gilead Partnership Reset - TipRanks
Arcus Biosciences ends STAR-121 lung cancer study and updates Gilead collaboration - Investing.com
Arcus Biosciences Incdiscontinues phase 3 star-121 study with Gilead due to futility - marketscreener.com
Zurcher Kantonalbank Zurich Cantonalbank Purchases 19,741 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stake Lowered by Miller Howard Investments Inc. NY - MarketBeat
Gilead Sciences (NASDAQ:GILD): A Value Screen Candidate with Strong Profitability - ChartMill
Gilead Sciences to buy clinical-stage biotech Tubulis for up to $5 billion - MSN
Gilead Sciences, Inc. (GILD) is a trending stock: Facts to know before betting on it - MSN
Gilead Deepens Oncology Reach And HIV Prevention With Arcellx And Lenacapavir - Yahoo Finance
Gilead Sciences, Inc. $GILD Shares Acquired by AE Wealth Management LLC - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by GF Fund Management CO. LTD. - MarketBeat
Gilead Sciences, Inc. $GILD Position Raised by Asset Management One Co. Ltd. - MarketBeat
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
Citi Raises Gilead (GILD) Price Target Ahead of Q1 Biopharma Preview - Insider Monkey
Jim Cramer on Gilead Sciences: “I’d Hold On to It” - Insider Monkey
Gilead Sciences stock edges lower as research teams attend AACR26 to advance cancer therapies - Traders Union
Gilead (GILD) Extends Tender Offer for Arcellx (ACLX) to April 2 - GuruFocus
Gilead extends Arcellx tender offer again - MSN
Gilead Sciences (NASDAQ:GILD) Given New $130.00 Price Target at The Goldman Sachs Group - MarketBeat
Morgan Stanley Adjusts Gilead Sciences, Inc. (GILD) Outlook Ahead of Q1 Earnings - Insider Monkey
Goldman Sachs Adjusts Gilead Sciences Price Target to $130 From $125, Maintains Neutral Rating - Moomoo
Gilead extends Arcellx tender offer again (GILD:NASDAQ) - Seeking Alpha
Gilead Sciences (NASDAQ: ACLX) offers $115 per share plus CVR; deadline extended - Stock Titan
Gilead Sciences patents new GTPase KRAS G12D inhibitors - BioWorld News
Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $155 From $115, Maintains Overweight Rating - Moomoo
Gilead extends Arcellx tender offer to April 27 - Investing.com
Gilead extends Arcellx tender offer to April 27 By Investing.com - Investing.com India
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer - Business Wire
Mirae Asset Global Investments Co. Ltd. Grows Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gene Transplant Market Is Going to Boom | Novartis • Gilead Sciences • Kite Pharma • Bluebird Bio - openPR.com
Farther Finance Advisors LLC Raises Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stock Holdings Lowered by Assetmark Inc. - MarketBeat
GILD Stock Price, Quote & Chart | GILEAD SCIENCES INC (NASDAQ:GILD) - ChartMill
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus
Insider Selling: Gilead Sciences (NASDAQ:GILD) Insider Sells $422,880.00 in Stock - MarketBeat
Gilead Sciences CFO Dickinson sells $422k in stock - Investing.com
Gilead Sciences exec Mercier sells $422k in stock - Investing.com
Gilead Sciences (NASDAQ: GILD) CFO sells 3,000 shares under 10b5-1 plan - Stock Titan
Gilead (GILD) executive Johanna Mercier sells 3,000 shares under 10b5-1 plan - Stock Titan
Gauging Gilead Sciences (GILD) Valuation After Strong Multi‑Year Shareholder Returns - Yahoo Finance
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
Gilead Sciences' HIV Drug Shows Weaker-Than-Expected Persistence Nine Months After Launch, RBC Says - marketscreener.com
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
RBC Capital maintains Gilead Sciences stock rating on Yeztugo concerns - Investing.com
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
자본화:
|
볼륨(24시간):